A prospective, single-arm, multicenter phase II clinical study of chemotherapy with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma
Latest Information Update: 08 Jul 2023
At a glance
- Drugs Catequentinib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Toripalimab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
Most Recent Events
- 08 Jul 2023 New trial record
- 06 Jun 2023 Preliminary results (n=19; Between January 2022 and January 2023; At the data cutoff date on January 31, 2023) assessing the efficacy and safety of Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.